Compare · PRCT vs SYK
PRCT vs SYK
Side-by-side comparison of PROCEPT BioRobotics Corporation (PRCT) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PRCT and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 102.5x PRCT ($1.24B).
- PRCT has been more active in the news (11 items in the past 4 weeks vs 9 for SYK).
- Both have 25 recent analyst ratings on file.
- Company
- PROCEPT BioRobotics Corporation
- Stryker Corporation
- Price
- -
- -
- Market cap
- $1.24B
- $126.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 11
- 9
- Recent ratings
- 25
- 25
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest PRCT
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
- EVP, Chief Technology Officer Templin Barry L was granted 26,246 shares, increasing direct ownership by 38% to 95,199 units (SEC Form 4)
- EVP, CLO, CORP. SEC. Nouri Alaleh was granted 22,965 shares, increasing direct ownership by 22% to 128,034 units (SEC Form 4)
- EVP, CFO Waters Kevin was granted 29,527 shares, increasing direct ownership by 20% to 180,728 units (SEC Form 4)
- Chief Strat/Marketing Officer Sharma Pooja was granted 23,622 shares, increasing direct ownership by 27% to 111,181 units (SEC Form 4)
- President, CEO Wood Larry L bought $498,315 worth of shares (23,900 units at $20.85) (SEC Form 4)
- SEC Form 10-Q filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics downgraded by William Blair
- PROCEPT BioRobotics downgraded by Wells Fargo with a new price target
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation